Bestatin administration and the change in cellular immunity.
The change in cellular immunity by Bestatin (ubenimex) treatment--30 mg/day orally--was investigated in 23 gastrointestinal cancer patients for: 1), functional T cell subsets; 2), IL-2 receptor; 3), PHA-induced blastogenesis; and 4), PPD skin reaction. The absolute number of helper T cells (Th) and cytotoxic T cells (Tc) increased in 74 and 79% of cases, respectively, compared with pretreatment values. On the other hand, the absolute number of suppressor T cells (Ts) decreased in 79% of cases. IL-2 receptor increased in 56% of patients, PHA blastogenesis increased in 67% of patients and PPD skin reaction was elevated in 75% of cases comparing to pretreatment values. These results suggest that Bestatin could increase cellular immunity in cancer patients.
Yamagishi
H
H
2nd Dept of Surgery, Kyoto Prefectural University of Medicine, Japan.
Naito
K
K
Ueda
Y
Y
Itoi
S
S
Kohnosu
H
H
Kobayashi
M
M
Kubo
H
H
Matsuda
A
A
Oka
T
T
D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D005770:Gastrointestinal Neoplasms / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects*; D007428:Intradermal Tests; D007930:Leucine / Q000031:analogs & derivatives* / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects; D015375:Receptors, Interleukin-2 / Q000187:drug effects; D016176:T-Lymphocyte Subsets / Q000187:drug effects
D000903:Antibiotics, Antineoplastic; D015375:Receptors, Interleukin-2; D007930:Leucine; C012211:ubenimex